1. United States Food and Drug Administration. Prescribing information: MOUNJARO (tirzepatide) injection, for subcutaneous use. Rockville, MD: FDA; 2022. p. 1–28. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf. Accessed 5 Sept 2022.
2. European Commission. Mounjaro tirzepatide. Summary of product characteristics. Brussels: EC; 2022. p. 1–87. https://ec.europa.eu/health/documents/community-register/2022/20220915156773/anx_156773_en.pdf. Accessed 6 Oct 2022.
3. Pharmaceuticals and Medical Devices Agency (PMDA). Manjaro tirzepatide. General list entry. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/24994A8. Accessed 20 Oct 2022.
4. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398:143–55.
5. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503–15.